Abbott launches pivotal trial of Cephea mitral valve replacement device
Bitget2026/10/29 13:05- Abbott initiated the CROWN-MV pivotal trial to evaluate the safety and effectiveness of its investigational Cephea mitral valve replacement system.
- The study will enroll up to 585 patients in the U.S., Canada and Europe.
- Eligible patients have moderate-to-severe or severe mitral regurgitation or calcium-related valve dysfunction and cannot undergo surgery or transcatheter repair.
- Cephea delivers a replacement tissue valve through a catheter inserted into a leg vein, offering a minimally invasive approach.
- Researchers will present 30-day early feasibility outcomes for Cephea's third-generation delivery system at TCT 2026 on Nov. 1.
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
Updated version 2-BP reports the highest net profit in at least five years
AstraZeneca (AZN.US) Q3 profit growth surpasses expectations, driven mainly by oncology drugs
AstraZeneca (AZN.US) released its Q3 2026 results on October 30th. At constant exchange rates (CER), total revenue for the quarter increased by 7% year-on-year to $16.209 billions.
BP.US Q3 profits soar to 18-year high: Refining business becomes 'money-printing machine', CEO's reforms encounter strong tailwind
Benefiting from a surge in refining profit margins, BP's quarterly profit jumped to its highest level in 18 years.
Australian Dollar: Bias shifts back to neutral against US Dollar – UOB
Crypto prices
More
